Gabapentin
Product Images NDC 70518-3708

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-3708). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Mm2 (Gabapentin 500mg 10ml 70518 3708 01)

Mm2 (Gabapentin 500mg 10ml 70518 3708 01)
Gabapentin 500 mg/10 mL oral solution label with a 10 mL quantity. The label includes storage instructions to keep refrigerated and temperature guidelines. It shows the labeler as RemedyRepack Inc. and the manufacturer as Acella Pharma, Alpharetta, GA. The label displays RX only status, barcode, and a QR code.*
FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Gabapentin 250 mg/5 mL oral solution packaging label showing a quantity of 10 cups, each 10 mL, from RemedyRepack Inc. The label includes storage instructions to keep refrigerated and to store between 2-8°C with allowed excursions. It also includes a barcode, QR code, and manufacturer information for Acella Pharma, Alpharetta, GA.*
FDA Label Image

Equation (Figure 01)

Equation (Figure 01)
An equation illustrating the calculation of creatinine clearance (CLCr). The formula shows adjustment for age in years, weight in kilograms, serum creatinine in mg/dL, and includes a factor of 0.85 for female patients.*
FDA Label Image

Chemical Structure (Figure 02)

Chemical Structure (Figure 02)
Chemical structure of Gabapentin, showing a cyclohexane ring bonded to an aminomethyl group and an acetic acid group.*
FDA Label Image

Figure 1 (Figure 03)

Figure 1 (Figure 03)
A line graph comparing mean pain scores over 8 weeks between placebo and Gabapentin 3600 mg/day. The X-axis shows time in weeks, and the Y-axis shows mean pain score from 0 to 10. The graph includes a 4-week dose titration period and a 4-week fixed dose period. Gabapentin shows a decreasing pain score trend, while placebo remains relatively stable.*
FDA Label Image

Figure 2 (Figure 04)

Figure 2 (Figure 04)
A line graph depicting mean pain scores over a period of 7 weeks for three groups: placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The graph is divided into a 3-week dose titration period followed by a 4-week fixed dose period, showing trends in pain score changes for each group.*
FDA Label Image

Figure 3 (Figure 05)

Figure 3 (Figure 05)
A bar chart comparing the percentages of outcomes in two studies labeled Study 1 and Study 2. The chart shows results for placebo (PBO) and various doses of gabapentin (GBP 1800, 2400, 3600), with significant differences indicated by p-values (** p < 0.01, *** p < 0.001). Percentages range from 0% to 100%, with bars showing higher percentages for gabapentin compared to placebo in both studies.*
FDA Label Image

Figure 4 (Figure 06)

Figure 4 (Figure 06)
A scatter plot displaying the percentage difference on the y-axis against daily dose in milligrams on the x-axis. It compares three studies labeled a, b, and c, with distinct markers: black squares for study a, gray squares for study b, and white squares for study c, representing data points for daily doses from 600 mg to 1800 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.